Razelle Kurzrock, MD

Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center

Associate Director of Precision Oncology at the Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine

Founding Director of the Michels Rare Cancers Research Laboratories

Dr. Razelle Kurzrock, a leader in precision medicine and the development of novel cancer therapies, has been listed as one of the most important voices in precision medicine and is on the Web of Science list of most cited scientists globally. She has over 950 peer reviewed publications and has been principal investigator for over 100 early phase clinical trials, including early trial of 8 FDA-approved drugs. She is the Chair for the Early Therapeutics and Rare Cancers Committee (SWOG NCI), and along with the DART rare cancer study team, received the National Cancer Institute Director’s Award of Merit for Outstanding Work. Previously, she was Director of both the Center for Personalized Cancer Therapy and the Experimental Therapeutics Program, and Founder of the Rare Tumor Clinic at Moores Cancer Center at UC San Diego Health. Dr. Kurzrock is recognized for founding, developing and chairing one of the largest Phase 1 clinical trial departments globally while at the University of Texas MD Anderson Cancer Center. She has held Board positions in the National Comprehensive Cancer Network (NCCN), and currently is on the Board of the SWOG Cancer Research Network and WIN Consortium in cancer personalized medicine. She has an MD from the University of Toronto, and completed a Residency in Internal Medicine at Tulane University Hospital, and a Fellowship in Medical Oncology at MD Anderson.